Therapeutic-like properties of a dopamine uptake inhibitor in animal models of amphetamine addiction.
N-substituted benztropine (BZT) analogs are molecules that display high affinity for the dopamine transporter (DAT), therapeutic-like effects in animal models of cocaine abuse, and psychopharmacological characteristics consistent with those of a substitute medication for cocaine addiction. Since amphetamine (Amph) and cocaine share mechanisms of action at the DAT, we evaluated the effectiveness of a BZT analog in animal models of Amph addiction. We tested in mice and rats the effects of the BZT derivative, 3α-[bis(4-fluorophenyl)methoxy]-tropane (AHN-1055), on Amph-induced conditioned place preference (CPP), locomotor activity, sensitization, self-administration and ΔFosB accumulation in the nucleus accumbens (NAc). The results showed that AHN-1055 did not produce rewarding, stimulant, or sensitized locomotor effects in mice when administered alone but it readily blocked the rewarding, stimulant, and sensitizing effects of repeated Amph exposure. Furthermore, in mice undergoing conditioning in the CPP paradigm, the BZT analog prevented the accumulation of ΔFosB protein induced in the NAc shell region by Amph treatment. Notably, treatment with AHN-1055 dose-dependently reduced Amph self-administration in rats with a steady history of voluntary Amph intake. These results provide a straightforward demonstration that a BZT derivative with binding affinity for DAT exhibits high efficacy in animal models of Amph abuse, suggesting that the novel generation of BZT analogs could have wider therapeutic applications in stimulant-spectrum disorders than those previously recognized.
Velazquez-Sanchez
Clara
C
Biopsychology & Comparative Neuroscience, Cavanilles Institute (ICBiBE), University of Valencia-FGUV, Valencia, Spain.
Ferragud
Antonio
A
Renau-Piqueras
Jaime
J
Canales
Juan J
JJ
D000661:Amphetamine / Q000494:pharmacology; D019969:Amphetamine-Related Disorders / Q000188:drug therapy*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D001590:Benztropine / Q000031:analogs & derivatives* / Q000494:pharmacology; D003213:Conditioning, Psychological / Q000187:drug effects; D004195:Disease Models, Animal; D050483:Dopamine Plasma Membrane Transport Proteins / Q000037:antagonists & inhibitors / Q000502:physiology; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology*; D008297:Male; D051379:Mice; D009043:Motor Activity; D009714:Nucleus Accumbens / Q000187:drug effects / Q000502:physiology; D051381:Rats; D012201:Reward; D012646:Self Administration
D050483:Dopamine Plasma Membrane Transport Proteins; D018765:Dopamine Uptake Inhibitors; C464560:N-methyl-3-(bis(4'-fluorophenyl)methoxy)tropane; D001590:Benztropine; D000661:Amphetamine